Published in final edited form as:

Genesis. 2011 January ; 49(1): 24–35. doi:10.1002/dvg.20691.

Forced involution of the functionally differentiated mammary gland by overexpression of the pro-apoptotic protein Bax

Edmund B. Rucker III^{1,§}, Amber N. Hale¹, David C. Durtschi², Kazuhito Sakamoto³, and Kay-Uwe Wagner³

¹Biology Department, University of Kentucky, Lexington, KY 40506-0225

²Veterinary Teaching Hospital, University of Tennessee, Knoxville, TN 37996-4542

³Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5950

Abstract

The mammary gland is a developmentally dynamic, hormone-responsive organ that undergoes proliferation and differentiation within the secretory epithelial compartment during pregnancy. The epithelia are maintained by pro-survival signals (e.g. Stat5, Akt1) during lactation, but undergo apoptosis during involution through inactivation of cell survival pathways and upregulation of pro-apoptotic proteins. To assess if the survival signals in the functionally differentiated mammary epithelial cells can override a pro-apoptotic signal, we generated transgenic mice that express Bax under the whey acidic protein (WAP) promoter. WAP-Bax females exhibited a lactation defect and were unable to nourish their offspring. Mammary glands demonstrated: 1) a reduction in epithelial content, 2) hallmark signs of mitochondria-mediated cell death, 3) an increase in apoptotic cells by TUNEL assay, and 4) precocious Stat3 activation. This suggests that upregulation of a single proapoptotic factor of the Bcl-2 family is sufficient to initiate apoptosis of functionally differentiated mammary epithelial cells *in vivo*.

Keywords

mammary gland; epithelium; Bax; apoptosis; involution; lactation

Introduction

Mammary gland development is classically compartmentalized into four distinct phases: virgin, pregnancy, lactation, and involution. The contributions of hormones, signaling pathways, and genes that give rise to the mammary gland, from the progression of the rudimentary anlagen during embryonic development through the post-natal stages described above, has been intensely studied (Review, Hennighausen and Robinson, 2005). Although estrogen and progesterone are the predominant hormones responsible for development of the gland in the virgin and early pregnancy phases, prolactin directs the proliferation and differentiation of the epithelia during mid-pregnancy through the prolactin receptor PRL-R/Jak2/Stat5 signaling pathway. Jak2-Stat5 signaling is persistent through the lactation phase for transcriptional activation of milk protein genes, and drops at the lactation-involution transition phase. Involution proceeds through: 1) an initial reversible phase marked by programmed cell death of secretory epithelium without remodeling of the lobuloalveolar

[§]Corresponding author Edmund.rucker@uky.edu 1-859-257-2175.

structure, followed by 2) an irreversible phase characterized by remodelling of the gland by proteases (e.g. matrix metalloproteinases, MMPs) and macrophages (Lund et al, 1996).

Forced involution, initiated at lactation day 10, triggers apoptosis in response to milk stasis within the alveolar lumen and the precipitous drop in lactogenic hormones (e.g. prolactin) (Feng et al, 1995). The lactation-involution transition is regulated, in part, by the contrasting activation of Stat5 and Stat3. Stat5 phosphorylation is maintained through lactation but drops precipitously at the onset of involution, while Stat3 phosphorylation is initiated as the gland enters involution (Liu et al, 1996; Philp et al 1996). Conditional deletion of *Stat5* results in the loss of mammary epithelium during mid-pregnancy and lactation, suggesting that this transcription factor is required for cell survival. In contrast, transgenic overexpression of Stat5 or gene ablation of *Stat3* delays the involution process (Iavnilovitch et al, 2002; Chapman et al, 1999). Similarly, loss of Socs3, a negative regulator of the Jak-Stat pathway, leads to an increased rate of involution via increased Stat3 activity (Sutherland et al, 2006). In addition to the Jak-Stat pathway, genetic modifications within the IGF and Akt1 signaling pathways reveal their importance. Transgenic IGF-1 or IGF-2 mice have delayed involution, while IGFBP5 overexpressors have increased apoptosis (Neuenschwander et al, 1996; Moorehead et al, 2001; Tonner et al, 2002). Downstream in the IGF signaling pathway, overexpression of PTEN or Akt1 in transgenic models displayed accelerated or delayed involution phases, respectively (Schwertfeger et al, 2001; Dupont et al, 2002; Ackler et al, 2002). Recently, Stat5 has been demonstrated to transcriptionally regulate Akt1, and conditional expression of Stat5 leads to persistent Akt1 activation and delayed involution (Creamer et al, 2009). In addition, PTEN ablation increased the survival of alveolar cells similar to the Akt1 overexpression (Li et al, 2002).

Programmed cell death (PCD), an important physiological process that is necessary for development, is classified either as either: Type I (apoptosis), Type II (autophagy), or Type III (non-lysosomal vesiculate degradation). Apoptosis can be generally stratified into a three-tiered molecular cascade system consisting of “elicitor” death receptors (e.g. TNFR1, TNFR2, Fas) (Ashkenazi et al, 1998; Singh et al, 1998), Bcl-2 family member “mediators” (e.g. Bcl-2, Bcl-X_L, Bcl-X_S, Bax, Bcl-W) (Adams J.M., 1998; Chao and Korsmeyer, 1998; Yang and Korsmeyer, 1996) and the caspase “executioners” (Alnemri et al., 1996; Cryns and Yuan, 1998; Thornberry and Lazebnik, 1998). The mammary gland is an advantageous organ to profile the stages of involution, as a forced involution allows for the synchronization of the biochemical processes. In the context of cell death programs, the involution phase exhibits one of the most dramatic physiological responses, with around 80% of the mammary epithelial cells undergoing programmed cell death (Marti et al, 1994). The cohort of signaling pathways and cell death genes necessary for this transitional period has been reviewed extensively (Baxter et al, 2007; Green et al, 2004; Stein et al, 2007). Although microarray and proteome analyses have revealed a predicted cast of proteins and highlighted biochemical pathways involved in involution, the most revealing studies have stemmed from mouse models (Clarkson et al, 2004; Stein et al, 2004).

Bcl-2 family members are considered the gatekeepers of the mitochondrial-mediated apoptosis, with the fate of the cell dependent upon the relative levels of the individual proteins. Bcl-2-like proteins can be subdivided into two distinct groups, those that are pro-apoptotic (e.g. Bax, Bcl-X_S, Bid, and Bad) and anti-apoptotic (e.g. Bcl-2, Bcl-X_L, and Bcl-W). *Bcl-x_L* and *Bax* are the two most prominent Bcl-2 family members expressed in mammary tissue. *Bcl-x_L* mRNA levels are low in virgin mammary tissue, but increase during pregnancy in parallel with Stat5 activation and cell differentiation. *Bcl-x_L* mRNA levels decrease during lactation, but increase again sharply within 48 hours of involution. Similarly, *Bax* mRNA levels increase with the onset of involution (Heermeier et al., 1996). Within the Bcl-2 family, several models highlight their influence on the maintenance of the

secretory epithelium. We have shown previously that the mammary gland-specific deletion of *Bcl-x_L* resulted in an increase in apoptosis and hastened involution (Walton et al, 2002). In the Bax-deficient mammary gland, involution is initially delayed but resembles the wild-type gland at involution day 10 after remodelling is completed (Schorr et al, 1999). Although Bax-deficient mammary glands have a delayed early involution, the loss of Bax does not rescue the accelerated cell death in *Bcl-x_L*-null mammary epithelium in our conditional knockout of *Bcl-x_L* (Walton et al, 2002). These studies show a cell- and developmental-specific dependence on Bax-mediated apoptosis. Ablation of *Bax* or enforced expression of Bcl-2 (WAP-Bcl-2 transgenic) delays but does not prevent involution, and promotes mammary tumor development (Jager et al, 1997; Schorr et al, 1999; Shibata et al, 1999; Furth et al, 1999).

To date, it has not been addressed whether upregulation of a single proapoptotic factor is sufficient to initiate involution and remodeling of the functionally differentiated mammary epithelium. To address this issue, we generated transgenic mice that express Bax under a mammary gland-specific promoter that is upregulated during secretory differentiation. Wap-Bax transgenic females display a lactation defect due to an increase in cell death and premature involution from ectopic Stat3 activation. This suggests that upregulation of Bax can override the pro-survival signaling functions of Stat5 and Akt1 in the lactating mammary gland.

Results

WAP-Bax transgenic mice exhibit impaired alveologenesis

Co-injection of the WAP-Bax transgene (Figure 1a) and a K14-agouti construct gave 5 independent founder lines out of 72 progeny as determined by PCR analysis (Figure 1b). Previous characterization of co-injected transgenes with the K-14 agouti demonstrated 95% co-integration, which allowed for visual determination of transgene inheritance (Kucera et al, 1996). All WAP-Bax lines also carried the K-14 agouti transgene, making it possible to distinguish bi-transgenic mice by a phaeomelanin (yellow) coat color (Figure 1c-d). Q-PCR was performed to establish copy number of the WAP-Bax transgenic lines, with a range of 1 to 3 copies of the transgene per line. Upon establishing germline transmission of the WAP-Bax transgene, F1 females were mated with control C57 males to determine effects on mammary gland development. Out of the 5 lines, 2 lines that demonstrated protein expression (IR5, IR15) could not support litters at lactation day 1 (L1). Neonates from WAP-Bax dams did not have milk 'spots', but could be fostered onto control lactating females (Figure 1e-f). Therefore, the defect was not a suckling defect with the neonates but the transgenic dams.

Whole mount analysis showed that control mammary glands at lactation day 1 predominantly consisted of secretory epithelia (Figure 2a). In addition, there was a distinct 'rounded' morphology to the alveoli. In contrast, WAP-Bax mammary glands demonstrated a reduced epithelial compartment and altered 'star-shaped' alveoli (Figure 2b-c). Hematoxylin-eosin staining of paraffin-embedded mammary glands showed normal, uniform secretory epithelia in the control glands, but reduced epithelia with altered morphology in the postpartum WAP-Bax transgenic glands (Figure 3). Epithelia in the mutant glands displayed increased signs of apoptosis; condensed cells had pyknotic nuclei with many being released into the lumen (Figure 3d).

Activation of an apoptotic program in response to expression of Bax

To determine the activation of the apoptotic program, a series of immunohistochemistry (IHC) experiments were performed. For these experiments, the IR15 line, which showed the

highest expression and greatest loss of epithelia, was used. At lactation day 1, expression of Bax was confined to the epithelial compartment of WAP-Bax mammary glands, but not detected in the controls (Figure 4). Upon Bax-mediated permeabilization of the mitochondria outer membrane, it was expected that cytochrome C is released, culminating in the activation of caspase 3 downstream of the apoptosome. Using IHC, we detected cytochrome C, apaF1 localization, and active caspase 3 within the cytosol of mammary epithelial cells of WAP-Bax transgenic females (Figure 5). This clearly suggests that overexpression of Bax is sufficient to elicits a classical mitochondria-mediated apoptotic program of functionally differentiated mammary epithelial cells.

Secretory mammary epithelial cells in WAP-Bax females are lost due to apoptosis

Upregulation of Bax normally coincides with the first phase of involution, which precedes the actual remodeling process two to three days later (Heermeier et al, 1996; Schorr et al, 1999). To confirm that continuous expression of exogenous Bax is sufficient to induce the second and terminal stage of apoptosis, we performed TUNEL staining (Figure 6). As expected, mammary glands of postpartum control females did not reveal apoptotic cells. In contrast, mammary glands of WAP-Bax transgenic mice had high levels of TUNEL-positive cells in the epithelial compartment. Transgenic lines IR62 (Figure 6B) and IR32 (Figure 6F) which expressed less Bax had also fewer TUNEL-positive cells compared to lines IR5 and IR15 (Figure 6C-E). Clusterin is a glycoprotein that is found to be expressed at high levels during pregnancy and involution, but is suppressed during lactation (French et al, 1996). Due to its expression profile, it is a marker for the lactation-involution transition. Clusterin was found by IHC in the WAP-Bax mammary glands and not in the control glands (Figure 7). More importantly, nuclear pStat3 was not present in control glands but was found in transgenic glands (Figure 8). pStat5 was expressed in control and transgenic glands as well. In line IR15, where most of the epithelia was already lost, pStat3 and pStat5 was not detected. Overall, these data suggest that the lactation defect in WAP-Bax females is due to a 'forced involution' process and loss of the secretory epithelia due to classical pStat3-mediated apoptosis.

Discussion

Programmed cell death (PCD) is a requisite cellular mechanism for development and homeostasis. Apoptosis, Type I PCD, can proceed via extrinsic or intrinsic pathways. Extrinsic pathways rely on apoptosis initiation by receptors at the cell surface, while intrinsic pathways from internal signals such as cellular damage (Chipuk and Green, 2005). Both pathways can converge on the mitochondria to mediate the cell death program. Bax, a pro-apoptotic protein from the Bcl-2 protein family, can induce pore formation in the mitochondria that ultimately leads to mitochondria outer membrane permeabilization (MOMP). Once MOMP occurs, cytochrome C is released from the damaged mitochondria, thus triggering apoptosome formation, caspase activation, and DNA degradation. Alternatively, release of additional mitochondrial proteins (e.g. AIF, OMI, and EndoG) can lead to necrosis through caspase-independent events (Chipuk and Green 2005; Portier and Tagliabue, 2006).

Other genetic studies from mouse models have revealed roles for Bax in regulating apoptosis in reproductive tissues. *Bax*-null mice have phenotypes within the testis and ovary. Males are sterile from the developmental failure of primary spermatocytes to mature into secondary spermatocytes, thus prompting a wave of apoptosis in the adolescent testis (Knudsen et al, 1995). Females are endowed with three times the population of primordial follicles compared to wild-type females. In addition, the reproductive lifespan of *Bax*^{-/-} females is longer due to reduced atresia (Perez et al, 1999). Bax is also involved with primordial germ cell (PGC) development in the fetus. Bax insures the apoptotic death of

ectopic PGCs that fail to arrive at the indifferent gonad (Stallock et al, 2003). Moreover, once PGCs colonize the fetal gonads, we have shown that Bax and Bcl-X_L regulate the survival of the germ cells (Rucker et al, 2000). Reduction of Bcl-X_L in PGCs leads to a sterile ‘Sertoli cell only’ phenotype in the male, and a 30-fold reduction in primordial follicle in the male. The loss of germ cell populations is restored by the concomitant loss of Bax in PGCs. Previously we have shown that the secretory epithelia of the mammary gland are also impacted by the loss of *Bax* or *Bcl-X_L*. These studies show a cell- and developmental-specific dependence on Bax-mediated apoptosis.

Our WAP-Bax transgenic model demonstrated a ‘forced involution’ and premature cessation of lactation at parturition. The cell death we find is due to a caspase-dependent induction of apoptosis, as determined by active caspase-3 IHC and TUNEL assay. Although Stat5 and Akt1 promote cell survival in the mammary gland during pregnancy and lactation, the ectopic overexpression of Bax overcomes these signals. Bax is regulated by Akt1 phosphorylation at Ser¹⁸⁴, which serves to maintain the cytosolic localization of Bax and prevent its mitochondrial targeting (Gardai et al, 2004). Since Akt1, Bcl-2, and Bcl-x_L are all cleaved by caspases, initial caspase-3 activation would provide a positive feedback loop to inhibit these pro-survival proteins (Widmann et al, 1998; Bachelder et al, 1999; Cheng et al, 1997; Clem et al, 1998). It is unclear as to the mechanism of pStat3 activation, although either induction of c-src or caspase-mediated degradation of Socs3 could lead to premature Stat3 phosphorylation. An additional cell survival mechanism that the mammary gland would utilize is autophagy. Autophagy is active in the L1 murine mammary glands (unpublished observations; EBR, ANH), which normally would serve to sequester damaged mitochondria into autophagosomes for turnover. Apparently, the 2 transgenic WAP-Bax lines with lactation defects have overcome the normal capacity of autophagy as a survival pathway within the epithelia. Interestingly, PUMA-dependent activation of Bax has been shown to concurrently induce autophagy of mitochondria (mitophagy) and a pro-apoptotic response (Yee et al, 2009). Thus, our WAP-Bax model may not only have an increase in Bax-mediated apoptosis but also Bax-dependent autophagy. Quantitation of autophagosomes in the WAP-Bax model with the transgenic GFP-LC3 autophagy reporter line would establish whether both of these processes are coordinately activated (Mizushima et al, 2004). Some cells could be lost from autophagic cell death, although the abundance of pyknotic nuclei and TUNEL-positive cells argue for apoptosis as the central programmed cell death mechanism.

There are two classical stages of mammary gland involution: the programmed cell death-driven reversible phase and the remodelling irreversible phase. However, gene expression studies of the early phase has demarcated seven signature profiles: 1) a 12-hour peak, 2) a 24-hour peak, 3) a 24-hour increase with persistent expression, 4) a 24-hour peak with a slow decrease, 5) a 72-96 hour peak, 6) a delayed expression for 48 hours, and 7) a delayed expression with peak after 96-hours (Baxter, et al, 2007). *Bax* mRNA is found in the fourth group with a 24-hour peak and slow decrease. As previously stated, this is the developmental window when Bax has an effect on involution. From our study, Bax also has a dramatic effect on the survival of the secretory epithelia around parturition. This highlights the dynamic plasticity of the mammary gland; epithelia poised with the requisite proteome to carry out programmed cell death given the proper internal signal or environmental cue. In summary, overexpression of the pro-apoptotic protein Bax in the mammary gland resulted in a lactation defect because of increased levels of apoptosis within the functionally differentiated mammary epithelial cell compartment. This WAP-Bax transgenic model of ‘forced involution’ demonstrated that upregulation of a single pro-apoptotic factor of the Bcl-2 family is sufficient to initiate programmed cell death of functionally differentiated mammary epithelial cells *in vivo*.

Methods

Generation of transgenic mice

The WAP-Bax construct was digested with *NotI* and gel purified with the Qiagen Gel Extraction Kit. The keratin 14 (K14)-agouti transgene (Kucera et al, 1996) was digested with *Clal* and also gel purified. Transgenes were co-injected at a final concentration of 2 μ g/ml into pronuclear-staged FVB embryos. Pups (3 weeks old) were genotyped for the Wap-Bax transgene with the following PCR primers and reaction conditions: forward (5'-TAG AGC TGT GCC AGC CTC TTC-3'); reverse (5'-GAC ACA GTC GAC TCA GAA CAT CTT CTT CCA G-3'); cycling conditions of 94°C for 5 min (1 cycle), 94°C for 30 sec, 58°C for 30 sec, 72°C for 1 min (32 cycles), and a final step of 72°C for 5 minutes. The product of 650 base pairs was resolved on a 1.5% agarose gel. Founders were backcrossed with C57/BL6 mice for 5 generations. WAP-Bax transgene copy number was determined using exon 3 and exon 4 specific primers paired with an exon 3-specific TaqMan probe (5'-6FAM ATG CGT CCA AGA AGC TGA GCG TAMRA-3' at 200nM final) with cycling conditions of 50°C for 2 min (1 cycle), 95°C for 10 min, 95°C 15 sec, 60°C for 1 min (40 cycles) on an ABI Prism 7700 thermocycler. Copy number was normalized to the endogenous Bcl-X_L gene (2 copies).

Isolation and preparation of mammary glands

At lactation day 1 of the second pregnancy, transgenic and non-transgenic females were anesthetized with 2.5% (v/v) avertin and then euthanized. Mammary glands were surgically removed and fixed in 10% buffered formalin overnight at 4°C. Tissues were placed in 70% ethanol, paraffin embedded, sectioned onto Superfrost slides (Fisherbrand).

Staining of mammary gland whole mounts

Mammary glands were harvested and fixed overnight in 10% (v/v) neutral buffered formalin followed by defatting in acetone overnight. Samples were rehydrated in 70% (v/v) ethanol for 30 minutes and then distilled water for 15 minutes. Staining was performed overnight with Alum carmine followed by dehydrating the following day (35% ethanol for 30 minutes; 50% ethanol for 30 minutes; 70% ethanol for 30 minutes; 95% ethanol for 30 minutes; 100% ethanol overnight). Clearing was done with xylene overnight, and then mammary glands were compressed between slides overnight, released and expanded 6 hours before cover slipping with Permount.

Immunohistochemistry

Mammary glands (lactation day 1) were fixed in 10% (v/v) neutral buffered formalin solution (Sigma) overnight, transferred to 70% ethanol, paraffin-embedded and then sectioned at 5 μ m. Sections were deparaffinized through ethanol, rehydrated in water, and placed in 0.03% (v/v) hydrogen peroxide in methanol for 30 min at room temperature. Sections were rinsed in 1 $\times$ PBS, treated with Target Unmasking Solution (Vector) at 100°C for 10 min, slow cooled an additional 10 min, and finally rinsed in 1 $\times$ PBS. Blocking was performed with 10% serum at room temperature for 30 min followed by the addition of Bax antibody, (1:200; B.D. PharMingen 13686E), Cytochrome C (1:50, B.D. PharMingen SC7159), Caspase-3 (1:50, Santa Cruz 556425), and Active Caspase-3 (1:50, B.D. PharMingen 559565) for overnight incubation at 4°C. Upon washing in 1 $\times$ TBS, peroxidase-conjugated secondary antibody (1:400) was added for 1 hr at room temperature. After rinsing in 1 $\times$ TBS, samples were incubated in ABC solution and treated with DAB (Vector Laboratory) according to manufacturer's protocol). Slides were counterstained with Methyl Green 0.1%, Nuclear Fast Red, or Hematoxylin QS (Vector laboratories) and mounted with Permount (Sigma).

Measurement of apoptosis mammary gland epithelial cells

For quantitation of apoptotic cells, the TUNEL-based Apoptag assay was performed according to the manufacturer on paraffin-embedded sections (Intergen). Briefly described, mammary gland tissue sections were deparaffinized, quenched in 3% hydrogen peroxidase and incubated with terminal transferase. After applying the anti-digoxigenin conjugate, the color was developed in DAB peroxidase substrate for 6 minutes. Samples were counterstained with methyl green (Vector Labs).

Acknowledgments

This work was supported, in part, by the Public Health Service grant CA117930 (to K.U.W.).

References

- Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. *Oncogene*. 2002; 21:198–206. [PubMed: 11803463]
- Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. *Science*. 1998; 281:1322–1326. [PubMed: 9735050]
- Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. Human ICE/CED-3 protease nomenclature. *Cell*. 1996; 87:171. [PubMed: 8861900]
- Ashkenazi A, Vishva MD. Death Receptors: Signaling and Modulation. *Science*. 1998; 281:1305–1308. [PubMed: 9721089]
- Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR, Mercurio AM. p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. *J Cell Biol*. 1999; 147:1063–1072. [PubMed: 10579725]
- Baxter FO, Neoh K, Tevendale MC. The beginning of the end: death signaling in early involution. *J Mammary Gland Biol Neoplasia*. 2007; 12:3–13. [PubMed: 17340185]
- Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. *Annu Rev Immunol*. 1998; 16:395–419. [PubMed: 9597135]
- Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. *Genes Dev*. 1999; 13:2604–2616. [PubMed: 10521404]
- Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM. Conversion of Bcl-2 to a Bax-like death effector by caspases. *Science*. 1997; 278:1966–1968. [PubMed: 9395403]
- Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? *Nat Rev Mol Cell Biol*. 2005; 6:268–275. [PubMed: 15714200]
- Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in postlactational regression. *Breast Cancer Res*. 2004; 6:R92–109. [PubMed: 14979921]
- Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, Kastan MB, Griffin DE, Earnshaw WC, Veluona MA, Hardwick JM. Modulation of cell death by Bcl-XL through caspase interaction. *Proc Natl Acad Sci U S A*. 1998; 95:554–559. [PubMed: 9435230]
- Creamer BA, Sakamoto K, Schmidt JW, Triplett AA, Moriggl R, Wagner KU. Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. *Mol Cell Biol*. 2010; 30:2957–2970. [PubMed: 20385773]
- Cryns V, Yuan J. Proteases to die for. *Genes Dev*. 1998; 12:1551–1570. [PubMed: 9620844]
- Dupont J, Renou JP, Shani M, Hennighausen L, LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. *J Clin Invest*. 2002; 110:815–825. [PubMed: 12235113]
- Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. *J Cell Biol*. 1995; 131:1095–1103. [PubMed: 7490285]

- French LE, Soriano JV, Montesano R, Pepper MS. Modulation of clusterin gene expression in the rat mammary gland during pregnancy, lactation, and involution. *Biol Reprod.* 1996; 55:1213–1220. [PubMed: 8949876]
- Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jager R. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. *Oncogene.* 1999; 18:6589–6596. [PubMed: 10597263]
- Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL, Henson PM. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. *J Biol Chem.* 2004; 279:21085–21095. [PubMed: 14766748]
- Green KA, Streuli CH. Apoptosis regulation in the mammary gland. *Cell. Mol. Life Sci.* 2004; 61:1867–1883. [PubMed: 15289930]
- Heermeier K, Benedict M, Li M, Furth P, Nunez G, Hennighausen L. Bax and Bcl-xs are induced at the onset of apoptosis in involuting mammary epithelial cells. *Mech.Dev.* 1996; 56:197–207. [PubMed: 8798158]
- Hennighausen L, Robinson GW. Information networks in the mammary gland. *Nat Rev Mol Cell Biol.* 2005; 6:715–25. [PubMed: 16231422]
- Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. *Mol Cancer Res.* 2002; 1:32–47. [PubMed: 12496367]
- Jager R, Herzer U, Schenkel J, Weiher H. Overexpression of Bcl- 2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. *Oncogene.* 1997; 15:1787–1795. [PubMed: 9362445]
- Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. *Science.* 1995; 270:96–99. [PubMed: 7569956]
- Kucera GT, Bortner DM, Rosenberg MP. Overexpression of an Agouti cDNA in the skin of transgenic mice recapitulates dominant coat color phenotypes of spontaneous mutants. *Dev Biol.* 1996; 173:162–173. [PubMed: 8575618]
- Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, Hennighausen L, Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. *Development.* 2002; 129:4159–4170. [PubMed: 12163417]
- Liu X, Robinson GW, Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. *Mol Endocrinol.* 1996; 10:1496–506. [PubMed: 8961260]
- Lund LR, Rømer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Danø K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. *Development.* 1996; 122:181–93. [PubMed: 8565829]
- Marti A, Jehn B, Costello E, Keon N, Ke G, Martin F, Jaggi R. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. *Oncogene.* 1994; 9:1213–1223. [PubMed: 8134124]
- Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell.* 2004; 15:1101–1111. [PubMed: 14699058]
- Moorehead RA, Fata JE, Johnson MB, Khokha R. Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. *Cell Death Differ.* 2001; 8:16–29. [PubMed: 11313699]
- Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. *J Clin Invest.* 1996; 97:2225–2232. [PubMed: 8636401]
- Perez GI, Tao XJ, Tilly JL. Fragmentation and death of ovulated oocytes. *Mol Hum Reprod.* 1999; 5:414–420. [PubMed: 10338364]
- Philp JA, Burdon TG, Watson CJ. Differential activation of STATs 3 and 5 during mammary gland development. *FEBS Lett.* 1996; 396:77–80. [PubMed: 8906870]
- Portier BP, Taghialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. *J Biol Chem.* 2006; 281:40493–40502. [PubMed: 17090549]

- Rucker EB III, Dierisseau P, Wagner KU, Garrett L, Wynshaw-Boris A, Flaws JA, Hennighausen L. Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. *Mol Endocrinol.* 2000; 14:1038–1052. [PubMed: 10894153]
- Schorr K, Li M, Bar-Peled U, Lewis A, Heredia A, Lewis B, Knudson CM, Korsmeyer SJ, Jäger R, Weiher H, Furth PA. Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo. *Cancer Res.* 1999; 59:2541–2545. [PubMed: 10363969]
- Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. *Mol Endocrinol.* 2001; 15:867–881. [PubMed: 11376107]
- Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. *EMBO J.* 1999; 18:2692–2701. [PubMed: 10329616]
- Singh A, Ni J, Aggarwal BB. Death domain receptors and their role in cell demise. *J Interferon Cytokine Res.* 1998; 18:439–450. [PubMed: 9712359]
- Stallock J, Molyneaux K, Schaible K, Knudson CM, Wylie C. The pro-apoptotic gene Bax is required for the death of ectopic primordial germ cells during their migration in the mouse embryo. *Development.* 2003; 130:6589–6597. [PubMed: 14660547]
- Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. *Breast Cancer Res.* 2004; 6:R75–91. [PubMed: 14979920]
- Stein T, Salomonis N, Gusterson BA. Mammary Gland Involution as a Multi-step Process. *J Mammary Gland Biol Neoplasia.* 2007; 12:25–35. [PubMed: 17431797]
- Sutherland KD, Vaillant F, Alexander WS, Forrest NC, Holroyd S, McManus EJ. c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. *EMBO J.* 2006; 25:5805–5815. [PubMed: 17139252]
- Thornberry NA, Lazebnik Y. Caspases: Enemies Within. *Science.* 1998; 281:1312–1316. [PubMed: 9721091]
- Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CB. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. *Development.* 2002; 129:4547–4557. [PubMed: 12223411]
- Walton KD, Wagner KU, Rucker EB III, Shillingford JM, Miyoshi K, Hennighausen L. Conditional deletion of the bcl-x gene from mouse mammary epithelium results in accelerated apoptosis during involution but does not compromise cell function during lactation. *Mech Dev.* 2001; 109:281–293. [PubMed: 11731240]
- Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. *J Biol Chem.* 1998; 273:7141–7147. [PubMed: 9507028]
- Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for bcl-x_L and bcl-2, displaces bax and promotes cell death. *Cell.* 1995; 80:285–291. [PubMed: 7834748]
- Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH. PUMA- and Bax-induced autophagy contributes to apoptosis. *Cell Death Diff.* 2009; 16:1135–1145.

Figure 1. Generation of WAP-Bax transgenic lines

WAP-Bax transgenic mice were produced by pronuclear injection of the WAP-Bax and K14-agouti constructs. **a)** Schematic of WAP-Bax transgene, showing the *Bax* cDNA cloned into a WAP promoter-based plasmid. The WAP promoter, portions of exons 1 and 3, intron 3, intron 4, and downstream sequence are present. **b)** Gel electrophoresis of Bax PCR products from negative control or transgenic WAP-Bax lines IR5, IR15, IR20, IR32, and IR62. Lanes: 1, 100 bp ladder; 2, wild-type control; 3, line IR5; 4, line IR15; 5, line IR20; 6, line IR32; 7, line IR62. **c)** Coat color of bitransgenic WAP-Bax; K14-agouti mice. **d)** Coat color of non-transgenic littermate. **e)** Neonates (day 1 of lactation) from WAP-Bax IR15 dam, which have failed to recover milk after suckling. **f)** Neonates from WAP-Bax IR15 dam fostered onto control lactating dam.

Figure 2. Expression of Bax under regulation of the WAP promoter results in reduced epithelial content in the postpartum mammary gland

Whole mounts from lactation day 1 control (a) and WAP-Bax transgenic mice (b, c) show reduced epithelial compartments in the transgenic mice. In addition, the wild-type alveoli have a rounded morphology compared to patches of collapsed, 'star-shaped' alveoli in the transgenic mice (denoted by arrows). Fp=fat pad. Bar = 0.5 mm.

Figure 3. Presence of apoptotic cells in mammary glands of WAP-Bax transgenic females at lactation day 1

Hematoxylin-eosin staining of lactation day 1 mammary glands was performed on control (a) and WAP-Bax mice (b-d). a) Control glands show uniform epithelial morphology and large lipid droplets in the lumens. b) WAP-Bax glands show reduced epithelia and increased fat pad, and lumens have smaller lipid droplets. c) Altered morphology is apparent in the epithelium and at higher magnification (d). Apoptotic cells are present as characterized by pyknotic nuclei (arrows). Fp = fat pad. Bar (a-c) = 50microM. Bar (d) = 25microM.

Figure 4. Expression of Bax under regulation of the Wap promoter is confined to the epithelial compartment of the developing mammary gland in postpartum females

Bax IHC shows localized expression in WAP-Bax but not control lactation day 1 mammary glands. **a)** Bax protein is not found to be expressed in the control gland using IHC; **b)** negative control for wild-type gland. **c)** and **e)** reveal Bax confined to the epithelial compartment in WAP-Bax glands; **d)** and **f)** represent negative IHC controls. Counterstain was performed with nuclear fast red (**a-d**) or hematoxylin (**e, f**). Arrows point to positive cells/alveoli. Fp = fat pad. Bar = 100microM.

Figure 5. Misexpression of Bax in the secretory mammary epithelium causes mitochondria-triggered caspase activation

WAP-Bax glands showed IHC staining for cytochrome C (**b**), apaF1 (**d**), and active caspase 3 (**e**, **f**), whereas control glands did not show cytochrome C (**a**) or apaF1 staining (**c**). **e**) WAP-Bax gland revealed active caspase-3 IHC staining in the alveoli (denoted with arrow) but not in the duct (du). Counterstain was performed with nuclear fast red (**a**, **b**, **f**) or hematoxylin (**c**, **d**, **e**). Arrows point to positive cells/alveoli. Fp = fat pad; du = duct; lu = lumen. Bar (**a**, **b**, **e**, **f**) = 25microM. Bar (**c**, **d**) = 50microM.

Figure 6. Premature involution of secretory mammary epithelial cells in postpartum WAP-Bax transgenic females

WAP-Bax glands showed increased levels of apoptosis compared to control gland. **a)** Wild-type lactation day 1 mammary gland with no TUNEL-positive cells. **b)** WAPBax line IR62. **c, d)** WAP-Bax line IR15. **e)** WAP-Bax line IR5. **f)** WAP-Bax line IR32. Lines IR5 and IR15 (**c-e**), which have lactation defects, have increased levels of TUNEL-positive cells compared to lines IR62 and IR32 (**b** and **f**). Counterstain was performed with methyl green. Arrows point to positive cells. Fp = fat pad; lu = lumen. Bar = 100microM.

Figure 7. Clusterin expression in the lactating mammary gland

Clusterin expression, a marker for involution, was not found in the control lactation day 1 gland (a) but was present in the WAP-Bax gland (b). Counterstain was performed with hematoxylin. Arrows point to positive cells/alveoli. Fp = fat pad; lu = lumen. Bar = 50microM.

Figure 8. pStat3 and pStat5 expression in the WAP-Bax mammary gland
pStat3 (**a-d**) and pStat5 (**e-h**) immunolocalization in wildtype (**a, e**), IR15 (**c, g**), and IR20 (**d, h**) glands at L1. Negative control (no primary Ab) is shown for pStat3 (**b**) and pStat5 (**f**). Arrows show nuclear localization of pStat5 and pStat3. Counterstain was performed with hematoxylin. Bar = 50microm.